Investigational Drug Shows Survival Benefit in Advanced Lung Cancer Study

New Phase 3 trial data indicates that risvutatug rezetecan, an experimental antibody-drug conjugate, significantly extended overall survival for patients with advanced or relapsed small cell lung cancer. This marks a notable achievement as the first B7-H3–targeted ADC to demonstrate positive overall survival in any tumor type, paving the way for potential regulatory submission in China.